A Single-center, Prospective, Randomized controlled trial comparing the Effectiveness of different hydration schemes in preventing Acute kidney injury in patients unDergoing PCI

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040410

Enrollment

Unknown

Registered

2020-11-28

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

Iodixanol oral hydration group:The dosage of iodixanol depends on the type of examination, age, weight, cardiac output and the patient's general condition and the technique used. From 12 hours before

Iodixanol intravenous hydration group:The dosage of iodixanol depends on the type of examination, age, weight, cardiac output and the patient's general condition and the technique used. From 12 hours

Ioverol Oral Hydration Group:The dosage of ioverol depends on the type of examination, age, weight, cardiac output and the patient's general condition and the technology used. From 12 hours before the

Ioverol intravenous hydration group:The dosage of ioverol depends on the type of examination, age, weight, cardiac output, and the patient's general condition and the technique used. From 12 hours bef

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old; 2. ACS patients who are planning to undergo PCI; 3. eGFR >=30ml/min/1.73 m2 (based on the Chronic Kidney Disease Epidemiology Institute (CKD-EPI) equation); the patient and (or) family members agree to join the clinical trial and sign an informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are known to be allergic to iodine contrast agents; 2. Type I diabetes; 3. A history of dialysis; 4. Use over-iodine contrast agent in the past 3 days; 5. Uncontrollable hypertension (blood pressure> 180/110 mm Hg); 6. Combined with hypervolemia and hyponatremia; 7. Active compensatory heart failure; 8. Use nephrotoxic drugs or breastfeeding within 7 days before pregnancy or pregnancy; 9. Participated in other clinical trials in the past 4 weeks.

Design outcomes

Primary

Measure	Time frame
Incidence of post-contrast acute kidney injury;	—

Secondary

Measure	Time frame
Dialysis treatment rate within 30 days after injection of contrast agent;Mortality within 30 days of contrast injection;Changes in sCr and BUN indicators in 6 months;	—

Countries

China

Contacts

Public ContactZhuhua Yao

Tianjin People's Hospital

tjyzhpci@163.com+86 13902199877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026